Immunitybio is trading 4.1% up today at $7.75 as biotechnology stocks rally, with the sector ETF gaining 2.17%.
- The move appears driven by broader sector sentiment rather than a fresh company-specific catalyst, as healthcare outperfroms technology in a risk-off market environment.
- No new announcements have been released; the stock's performance follows recent volatility tied to an FDA warning letter regarding Anktiva promotional claims.